ArticleJournal of orthopaedic surgery and research2025
Risk factors for scoliosis progression in children with idiopathic short stature on growth hormone therapy.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Vitamin-D status in sixty adolescents with idiopathic scoliosis: An observational study.Pakistan journal of medical sciences · 2026Article
- Endocrine-informed monitoring of scoliosis in Prader-Willi syndrome: integrating neuroendocrine pathophysiology, growth hormone therapy, and pubertal transition.Frontiers in endocrinology · 2026Review
- Head kinematic analysis in idiopathic scoliosis: a case-control study.Journal of orthopaedic surgery and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo analyze the clinical characteristics of scoliosis in children with idiopathic short stature after growth hormone treatment, and to explore the influence of growth hormone treatment on the progression of scoliosis and the risk factors for the progression of scoliosis.
methodsA retrospective study of children with scoliosis treated with growth hormone between January 2021 and June 2024 was conducted, analyzing the clinical characteristics of scoliosis and comparing the progression rate of scoliosis between the exposure group and the control group. Independent risk factors for exacerbation of scoliosis were determined by univariate and multifactorial logistic regression analysis.
resultsIn this study, the average Cobb angle at initial diagnosis of scoliosis during recombinant human growth hormone (rhGH) therapy was 11.86° across all children, with a maximum value not exceeding 20°, consistent with mild scoliosis. Comparative analysis revealed significantly greater Cobb angles in females versus males at both initial angle (11.40 ± 1.72° vs. 12.25 ± 2.64 °, p<0.01) and outcome angle (10.83 ± 1.85° vs. 11.77 ± 2.60°, p < 0.01) And apical vertebrae were distributed in thoracic 10- lumbar 1 (64.17%). The progression rate of scoliosis in the exposure group was significantly higher than that in the control group, and the risk ratio was 4.26. In the exposed group, the scoliosis progression rate was 17.02% (8/39) in males versus 20.00% (13/52) in females (p = 0.69). Within controls, progression rates were 4.35% (2/44) in males and 4.44% (2/43) in females (p = 1.00). Univariate and multivariate logistic regression analyses showed that continued growth hormone treatment and the initial Cobb Angle were independent risk factors for scoliosis progression.
conclusion(1) Scoliosis developing in children with idiopathic short stature (ISS) receiving growth hormone (GH) therapy predominantly manifests as mild curvature. (2) If scoliosis develops during GH therapy, continued treatment may increase the risk of scoliosis progression. (3) Patients with smaller initial Cobb Angles are at higher risk of progression, necessitating closer clinical monitoring for this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.